Q4 2020 Medtronic PLC Earnings Call

DUBLIN, May 19, 2020 -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of Kyphon Assist™ Directional Cannula for use with.

The coronavirus pandemic slammed Medtronic in its fiscal fourth quarter as the medical technology company posted a 26% sales decline and 62% slide in earnings — leading MDT stock to drop.

Medtronic plc (MDT) today announced financial results for its fourth quarter and fiscal year 2020, which ended April 24, 2020. Medtronic’s results were also consistent with the impact felt across the MedTech industry from deferred procedures as a result of the pandemic. Medtronic is in a strong financial position, as represented by the increase in its cash dividend announced today, and the company continues to drive its long-term strategies.

Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 36th Annual Strategic Decisions Conference, held virtually, on Friday, May 29, 2020. Geoff Martha, chief executive officer of Medtronic, will make a presentation and will answer questions about the company beginning at 9:00 a.m. EDT (8:00 a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world.

Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

MSA Safety, Fresnius Medical Care, and LeMaitre Vascular are well-priced stocks on the rise with solid dividends.

Medtronic plc (MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval for the Android™ version of its Guardian™ Connect continuous glucose monitoring (CGM) system. The Guardian Connect system is a standalone CGM system that alerts patients of potential high or low sensor glucose events up to 60 minutes in advance and provides confidence to people living with diabetes who worry about fluctuating glucose levels and dangerous low glucose events.

Medical device company Medtronic Plc said Thursday it had net income of $646 million, or 48 cents a share, in its fiscal fourth quarter to April 24, down from $1.172 billion, or 87 cents a share, in the year-earlier period. Adjusted per-share earnings came to 58 cents, below the 96 cents FactSet consensus. Revenue fell 26% to $6.0 billion, below the $6.9 billion FactSet consensus. The numbers were in line with an update provided by the company on April 21, which detailed the impact of the coronavirus pandemic on operations and financials. "Medtronic's results were also consistent with the impact felt across the MedTech industry from deferred procedures as a result of the pandemic," the Dublin-based company said in a statement. "Medtronic is in a strong financial position, as represented by the increase in its cash dividend announced today, and the company continues to drive its long-term strategies." The company's board approved an increase in the quarterly dividend to 58 cents from 54 cents. It is not offering guidance because of the uncertainty created by the pandemic. Shares fell 1.1% premarket and are down 14% in the year to date, while the S&P 500 has fallen 8%.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Medtronic, Inc. New York, May 18, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Medtronic, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

Companies In The News Are: MDT, BJ, SNPS, EXPE.

Medical device makers have borne the brunt of the coronavirus outbreak as federal and state guidelines ask for elective surgeries such as hip and knee replacements and certain heart procedures to be delayed, sapping the demand for devices used in the surgeries. The company expects a slow recovery in its restorative therapies unit, which houses neuro-stimulation implants to treat chronic pain, and heart device unit, which sells valves. "We currently expect first quarter revenue growth to be modestly worse than the fourth quarter," said Chief Financial Officer Karen Parkhill.

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

The medical device giant's Q4 revenue and earnings fell well short of expectations. Here's why.

Medtronic shares were falling Thursday after the medical device manufacturer reported fourth quarter results that missed estimates as revenue fell 26% year over year in the quarter. The Dublin-based company reported fourth quarter earnings of 58 cents per share on revenue of $6 billion. Medtronic shares fell more than 2% to $96.10 in trading on Thursday.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Medtronic (MDT) delivered earnings and revenue surprises of -1.69% and 1.20%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.

The global case tally for the coronavirus that causes COVID-19 passed 5 million on Thursday after the biggest one-day increase since the start of the outbreak, as a top U.S. scientist cautioned that people should not rely on a vaccine and the labor market continued to show massive job losses.

Chubb, Clorox, Flower Foods, Medtronic and Northrop Grumman have all recently raised their dividends Continue reading...